| abstract |
A compound of formula (i) wherein X and Y are independently CH, N or N-oxide, provided that X and Y do not both represent CH; Z is CO or CS; R1 is alkyl, optionally substituted with one or more halogens; and R2, R3, R4 and R5 are each various organic groups. Such compounds have therapeutic utility, via inhibition of phosphodiesterase IV. A compound of formula (i) wherein X and Y are independently CH or N, provided that X and Y do not both represent CH; Z is CO; R1 is C1-6 alkyl, optionally substituted with halogen R2 is C1-4 alkylcarbonyl, C1-6 alkyl, C1-6 alkoxy-C1-6 alkyl, or C3-6 cycloalkyl, C4-10 heterocyclo (in which one or more of the atoms in the ring system is an element other than carbon, chosen from amongst nitrogen, oxygen or sulphur), C5-10 heteroaryl (in which one or more of the atoms in the ring system is an element other than carbon, chosen from nitrogen (and N-oxides), oxygen and sulphur) or C6-10 aryl any of which may be substituted with C1-6 alkoxy, C1-6 alkyl or C1-6 alkoxy-carbonyl; R3 is H, R4 is H; R5 is C6-10 aryl or C5-10 heteroaryl (in which one or more of the atoms in the ring system is an element other than carbon, chosen from nitrogen (and N-oxides), oxygen and sulphur), optionally substituted at any position with substituent(s) (in which R7 is C1-6 alkyl optionally substituted with halogen(s), halogen C1-6 alkoxy or CN); And N-oxides and pharmaceutically-acceptable salts thereof. |